Agios Pharma Enters into Exclusive License Deal

Agios Pharmaceuticals (AGIO) said Thursday that it has entered a global license agreement with Aurigene Discovery Technologies Limited to research, develop and commercialize small molecule inhibitors of an undisclosed cancer metabolism target.

Under the terms of the deal, Aurigene will provide Agios exclusive rights to its portfolio of novel small molecules for the undisclosed target. Financial terms of the agreement include a $3 million upfront payment and potential future milestone payments of up to $17 million per licensed product if certain development and regulatory milestones are achieved by Agios. Aurigene is also eligible to receive low single-digit royalties on product sales. Agios will conduct preclinical studies and, if successful, fund further global research and development, as well as regulatory and commercial activities.

By Jon Flanagan